natgillin/translations-raw huggingface dataset:
Protaphane 100 international units/ml suspension for injection in vial human insulin
Protaphane 100 internacionalnih jedinica/ml suspenzija za injekciju u bočici humani inzulin
Protaphane 100 international units/ml suspension for injection.
Protaphane 100 internacionalnih jedinica/ml suspenzija za injekciju.
Protaphane 40 international units/ml Suspension for injection
Protaphane 40 internacionalnih jedinica/ml Suspenzija za injekciju
Protaphane 40 international units/ml suspension for injection in vial human insulin
Protaphane 40 internacionalnih jedinica/ml suspenzija za injekciju u bočici humani inzulin
Protaphane 40 international units/ml suspension for injection.
Protaphane 40 internacionalnih jedinica/ml suspenzija za injekciju.
Protaphane can be used in children and adolescents.
Protaphane se može primjenjivati u djece i adolescenata.
Protaphane contains less than 1 mmol sodium (23 mg) per dose, i.e.
Protaphane sadrži manje od 1 mmol (23 mg) natrija po dozi tj.
Protaphane contains less than 1 mmol sodium (23 mg) per dose, i.e.
Protaphane sadrži manje od 1 mmol (23 mg) natrija po dozi, tj.
Protaphane contains sodium
Protaphane sadrži natrij
Protaphane FlexPen 100 international units/ml Suspension for injection
Protaphane FlexPen 100 internacionalnih jedinica/ml Suspenzija za injekciju
Protaphane FlexPen 100 international units/ml suspension for injection in pre-filled pen human insulin
Protaphane FlexPen 100 internacionalnih jedinica/ml suspenzija za injekciju u napunjenoj brizgalici humani inzulin
Protaphane FlexPen 100 international units/ml Suspension for injection in pre-filled pen Insulin human
Protaphane FlexPen 100 internacionalnih jedinica/ml Suspenzija za injekciju u napunjenoj brizgalici humani inzulin
Protaphane FlexPen is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
Protaphane FlexPen je napunjena brizgalica namijenjena uporabi s jednokratnim iglama NovoFine ili NovoTwist duljine do 8 mm.
Protaphane FlexPen is accompanied by a package leaflet with detailed instructions for use to be followed.
Uz Protaphane FlexPen priložena je Uputa o lijeku s detaljnim naputcima za primjenu koje treba slijediti.
Protaphane InnoLet 100 international units/ml Suspension for injection
Protaphane InnoLet 100 internacionalnih jedinica/ml Suspenzija za injekciju
Protaphane InnoLet 100 international units/ml suspension for injection in pre-filled pen human insulin
Protaphane InnoLet 100 internacionalnih jedinica/ml suspenzija za injekciju u napunjenoj brizgalici humani inzulin
Protaphane InnoLet 100 international units/ml Suspension for injection in pre-filled pen Insulin human
Protaphane InnoLet 100 internacionalnih jedinica/ml Suspenzija za injekciju u napunjenoj brizgalici humani inzulin
Protaphane InnoLet is a pre-filled disposable pen containing human insulin as isophane (NPH).
Protaphane InnoLet je jednokratna napunjena brizgalica koja sadrži humani inzulin u obliku izofana (NPH).
Protaphane InnoLet is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
Protaphane InnoLet je napunjena brizgalica namijenjena uporabi s jednokratnim iglama NovoFine ili NovoTwist duljine do 8 mm.
Protaphane InnoLet is accompanied by a package leaflet with detailed instructions for use to be followed.
Uz Protaphane InnoLet priložena je Uputa o lijeku s detaljnim naputcima za primjenu koje treba slijediti.
Protaphane is a human insulin with a gradual onset and long duration of action.
Protaphane je humani inzulin s postupnim početkom i dugim trajanjem djelovanja.
Protaphane is a human insulin with gradual onset and long duration of action.
Protaphane je humani inzulin s postupnim početkom i dugim trajanjem djelovanja.
Protaphane is essentially ‘sodium-free’.
Protaphane sadrži zanemarive količine natrija.
Protaphane is indicated for treatment of diabetes mellitus.
Protaphane je indiciran za liječenje šećerne bolesti.
Protaphane Penfill 100 international units/ml Suspension for injection
Protaphane Penfill 100 internacionalnih jedinica/ml Suspenzija za injekciju
Protaphane Penfill 100 international units/ml suspension for injection in cartridge human insulin
Protaphane Penfill 100 internacionalnih jedinica/ml suspenzija za injekciju u ulošku humani inzulin
Protaphane Penfill is accompanied by a package leaflet with detailed instructions for use to be followed.
Uz Protaphane Penfill priložena je Uputa o lijeku s detaljnim naputcima za primjenu koje treba slijediti.
PROTAPHANE suspension for injection in pre-filled pen.
PROTAPHANE suspenzija za injekciju u napunjenoj brizgalici.
Protaphane vial (100 international units/ml), Penfill and FlexPen:
Protaphane bočica (100 internacionalnih jedinica/ml), Penfill i FlexPen:
Protaphane vial (40 international units/ml) and InnoLet:
Protaphane bočica (40 internacionalnih jedinica/ml) i InnoLet:
Protaphane vial is accompanied by a package leaflet with detailed instructions for use to be followed.
Uz Protaphane bočicu priložena je Uputa o lijeku s detaljnim naputcima za primjenu koje treba slijediti.
Protaphane vials are for use with insulin syringes with the corresponding unit scale.
Protaphane bočice koriste se s inzulinskim štrcaljkama s odgovarajućom jediničnom skalom.
protease inhibitors (e.g. fosamprenavir, indinavir, ritonavir, saquinavir, tipranavir);
inhibitori proteaze (npr. fosamprenavir, indinavir, ritonavir, sakvinavir, tipranavir);
Protease inhibitors (PI)
Inhibitori proteaze (IP)
Protease Inhibitors (PI) - Boosted (with co-administration of low-dose ritonavir)
Inhibitori proteaze (IP) - pojačani (istovremeno primijenjenom niskom dozom ritonavira)
Protease inhibitors (PIs)
Inhibitori proteaze (PI)
Protease Inhibitors (PIs): Taking Aptivus may cause large decreases in the blood levels of other HIV protease inhibitors.
Inhibitori proteaze (IP): Uzimanje Aptivusa može izazvati velika smanjenja razine drugih inhibitora proteaze HIV-a u krvi.
Protease inhibitors including ritonavir and its combinations with other protease inhibitors affect P-gp (either as inhibitor or as inducer).
Inhibitori proteaze, uključujući ritonavir i njegove kombinacije s drugim inhibitorima proteaze, utječu na P-gp (ili kao inhibitor ili kao induktor).
protease inhibitors plasma
BENZODIAZEPINI
protease inhibitors suggest a possible 3-4
drugim inhibitorima proteaza ukazuju na
protease inhibitors, anti-infectives such as ketoconazole, azole antifungals, clarithromycin or telithromycin. carbamazepine, rifampicine, phenobarbital, phenytoin, efavirenz or St. John’s Wort (potential risk of reduced efficacy).
inhibitore proteaze, antiinfektivne lijekove poput ketokonazola, azolne antifungalne lijekove, klaritromicin ili telitromicin. karbamazepin, rifampicin, fenobarbital, fenitoin, efavirenz ili gospinu travu (potencijalni rizik smanjene djelotvornosti).
Protease inhibitors: careful monitoring for any occurrence of drug toxicity and /or lack of anti- viral efficacy, and dose
Inhibitori proteaze: paţljivo praćenje radi mogućeg razvoja toksičnosti lijeka i/ili izostanka antivirusne djelotvornosti te po potrebi prilagoĎavanje doze.
Protease inhibitors: careful monitoring for any occurrence of drug toxicity and /or lack of anti- viral efficacy, and dose adjustment if required.
Inhibitori proteaze: paţljivo praćenje radi mogućeg razvoja toksičnosti lijeka i/ili izostanka antivirusne djelotvornosti te po potrebi prilagoĎavanje doze.
Protease inhibitors: EVOTAZ in combination with other protease inhibitors is not recommended because co- administration may not provide adequate protease inhibitor exposure.
Inhibitori proteaze: Ne preporučuje se primjena lijeka EVOTAZ u kombinaciji s drugim inhibitorima proteaze jer njihova istodobna primjena možda neće pružiti odgovarajuću izloženost inhibitorima proteaze.
Protect from light
Zaštiti od svjetla.
Protect from light
Zaštititi od svjetla.
Protect from light
Čuvati na tamnom mjestu.
Protect from light.
Zaštitite je od svjetlosti.
Protect from light.
Zaštititi od svijetlosti.
Protect from light.
Zaštititi od svjetlosti
Protect from light.
Čuvati od zamrzavanja.
Protect the gas cylinders from shocks, falls, oxidising and flammable materials, moisture, sources of heat or ignition.
Spremnike s plinom zaštitite od udaraca, padova, oksidacije i zapaljivih materijala, vlage, izvora topline i zapaljenja.
Protect the medicine and pre-filled pen against direct sunlight.
Zaštitite lijek i napunjenu brizgalicu od izravnog sunčevog svjetla.
Protect the solution from direct sunlight.
Zaštitite otopinu od izravnog sunčevog svjetla.
Protect the surface to cushion impact. (See Figure A)
Zaštitite površinu da biste ublažili udarac. (vidjeti Sliku A)
Protect your Lyxumia pens from dust and dirt.
Zaštitite Lyxumia brizgalice od prašine i prljavštine.
Protect your OptiSet from dust and dirt.
Zaštitite svoj OptiSet od prašine i prljavštine.
Protection against hepatitis A and hepatitis B develops within 2-4 weeks.
Zaštita protiv hepatitisa A i hepatitisa B razvija se unutar 2 - 4 tjedna.
Protection against hepatitis B infections may not be obtained until after the second dose (see section 5.1).
Zaštita protiv infekcija hepatitisom B možda se neće postići prije primitka druge doze (vidjeti dio 5.1).
Protection against PCV 2 starts two weeks after vaccination and lasts for 23 weeks after vaccination.
Zaštita od virusa PCV 2 počinje dva tjedna nakon cijepljenja i traje 23 tjedna nakon cijepljenja.
Protection against PCV2 starts at two weeks after vaccination and for Mycoplasma hyopneumoniae it starts four weeks after vaccination.
Zaštita protiv PCV2 počinje dva tjedna nakon cijepljenja, a za bakteriju Mycoplasma hyopneumoniae počinje četiri tjedna nakon cijepljenja.
Protection category: tight against solid bodies larger than 1 mm, but not waterproof.
Kategorija zaštite: sustav za primjenu je zaštićen od ulaska krutih tvari promjera većeg od 1 mm, ali ne i od prodora vode.
Protection lasted 22 weeks after vaccination for PCV2 and 21 weeks after vaccination for Mycoplasma hyopneumoniae.
Zaštita je trajala 22 tjedna nakon cijepljenja protiv PCV2 i 21 tjedan nakon cijepljenja protiv bakterije Mycoplasma hyopneumoniae.
Protection lasted 23 weeks after vaccination for PCV2 and 16 weeks after vaccination for Mycoplasma hyopneumonia.
Zaštita je trajala 23 tjedna nakon cijepljenja za PCV2 i 16 tjedana nakon cijepljenja za bakteriju Mycoplasma hyopneumoniae.
Protection lasts for 22 weeks after vaccination for PCV2 and for 21 weeks after vaccination for Mycoplasma hyopneumoniae.
Zaštita traje 22 tjedna nakon cijepljenja protiv PCV2 i tijekom 21 tjedna nakon cijepljenja protiv bakterije Mycoplasma hyopneumoniae.
Protection of Eptifibatide Accord solution from light is not necessary during administration.
Za vrijeme primjene otopinu Eptifibatid Accord a nije potrebno štititi od svjetlosti.
Protection of Eptifibatide Accord solution from light is not necessary during administration.
Za vrijeme primjene otopinu Eptifibatid Accorda nije potrebno štititi od svjetlosti.
Protection of INTEGRILIN solution from light is not necessary during administration.
Za vrijeme primjene otopine INTEGRILIN nije potrebno štititi od svjetlosti.
Protection of piglets is achieved by colostrum intake.
Zaštita prasadi postiže se uzimanjem kolostruma.
Protection of surrounding skin areas
Zaštita okolnog područja kože
Protection starts one week after vaccination.
Zaštita počinje jedan tjedan nakon cijepljenja.
Protection starts three weeks after vaccination and lasts for 23 weeks after vaccination for PCV2 and for 16 weeks after vaccination for Mycoplasma hyopneumoniae.
Zaštita počinje tri tjedna nakon cijepljenja i traje 23 tjedna nakon cijepljenja za PCV2 te 16 tjedana nakon cijepljenja protiv bakterije Mycoplasma hyopneumoniae.
Protective Cap
Narančasti gumb
Protective cap
Zaštitni omot
Protective effectiveness against cholera was evaluated during two mass-vaccination campaigns conducted in Mozambique (December 2003 – January 2004) and Zanzibar (February 2009 – May 2010).
Zaštitna učinkovitost protiv kolere procijenjena je tijekom dvije kampanje masovnog cijepljenja provedene u Mozambiku (prosinac 2003. – siječanj 2004.) i Zanzibaru (veljača 2009. – svibanj 2010.).
Protective efficacy, % (95% CI)
Zaštitna djelotvornost, % (95% CI)
Protective immune response against CAV-2 associated respiratory disease is considered to last at least 3 years.
Zaštitna imunost na CAV-2 povezan s dišnom bolesti smatra se da traje najmanje 3 godine.
Protective immune response against CAV-2 associated respiratory disease is considered to last at least 3 years.
Zaštitni imuni odgovor na CAV-2 povezan s dišnom bolesti smatra se da traje najmanje 3 godine.
Protective immune response against CAV-2 associated respiratory disease is considered to last at least 3 years.
Zaštitni imunološki odgovor protiv CAV-2 povezan s dišnom bolesti smatra se da traje najmanje 3 godine.
Protective seal
zaštitni zatvarač
PROTECTIVE SLEEVE CONTAINING WALLET
ZAŠTITNA KOŠULJICA KOJA SADRŽI KARTONSKI OVITAK
Protein binding in human plasma is approximately 87% at therapeutic concentrations, and thusinteraction with other medicinal products, due to displacement is unlikely.
Vezanje za proteine plazme u ljudi iznosi otprilike 87% pri terapijskim koncentracijama i stoga interakcija lijeka s drugim lijekovima zbog istiskivanja nije vjerojatna.
Protein binding of ceftiofur and its major metabolite is high, approximately 70% – 90%.
Proteinsko vezanje ceftiofura i njegova glavnog metabolita visokih je vrijednosti, približno 70 - 90%.
Protein binding of cinacalcet is not affected by impaired hepatic function.
Oštećenje jetre ne mijenja vezanje sinakalceta za bjelančevine.
Protein binding of silodosin glucuronide is 91 %.
Vezanje silodozin glukuronida na proteine plazme je 91 %.
Protein binding to human serum protein in vitro is  13%.
Vezanje za proteine u ljudskom serumu in vitro je  13%.
Protein binding was not altered in subjects with mild or moderately impaired renal or hepatic function.
Vezanje za proteine nije bilo izmijenjeno u ispitanika s blagim ili umjerenim oštećenjem funkcije bubrega ili jetre.
Protein C contained in CEPROTIN is a normal constituent of human plasma and acts like endogenous protein C. Therefore experimental studies on tumorigenic or mutagenic effects - particularly in heterologous species - are not considered necessary.
Protein C koji se nalazi u lijeku CEPROTIN je normalan sastojak ljudske plazme i djeluje kao endogeni protein C. Stoga se smatra da nije potrebno provoditi eksperimentalna ispitivanja tumorogenih ili mutagenih učinaka - osobito u heterolognih vrsta.
Protein C is a vitamin K-dependent anticoagulant glycoprotein which is synthesised in the liver.
Protein C je o vitaminu K ovisan antikoagulantni glikoprotein koji se sintetizira u jetri.
Protein in the urine
Bjelančevine u mokraći
protein in the urine
proteini u urinu
protein in the urine (abnormal urine test)
proteini u mokraći (odstupanja u nalazima pretrage mokraće)
Protein in the urine (also called ‘proteinuria’): Very common (may affect more than 1 in 10 people) – this is very commonly seen in tests.
Proteini u mokraći (poznato i kao ‘proteinurija’): Vrlo često (mogu se javiti u više od 1 na 10 osoba) - vrlo se često može vidjeti u nalazima pretraga.
Protein in the urine (may show in your urine tests)
proteini u mokraći (mogu se vidjeti iz rezultata krvnih pretraga)
protein in the urine (proteinuria)
bjelančevine u mokraći (proteinurija)
protein in the urine (proteinuria)
proteini u urinu (proteinurija)
Protein in the urine, increased urine, kidney problems.
proteini u mokraći, pojačano mokrenje, problemi sa bubrezima.
Protein in the urine, occasionally severe and associated with side effects, such as swelling
proteini u mokraći, povremeno u velikoj količini i povezani s nuspojavama kao što je oticanje
Protein in urine (seen in tests)
Proteini u mokraći (primijećeni na pretragama)
protein in your urine
nalaz proteina u mokraći
Protein or blood in the urine, gallstones, painful urination
Proteini ili krv u mokraći, žučni kamenci, bolno mokrenje
Protein Sequence change
Promjena slijeda u proteinu
Protein urine present
Proteinurija
protein-losing gastroenteropathy, ileus, anal fistula
gastroenteropatija s gubitkom proteina, ileus, analna fistula
Proteinaceous particles may be present in the concentrate that appear as translucent to white, amorphous particles, some of which look fibrous.
U koncentratu mogu biti prisutne proteinske čestice koje izgledaju kao prozirne do bijele amorfne čestice, od kojih neke izgledaju vlaknasto.
proteins
proteina
proteins (albumin) in urine increase in levels of liver enzymes (ALT, AST) in the blood
proteini (albumin) u mokraći povišena razina jetrenih enzima (ALT, AST) u krvi
proteins in urine
proteini u mokraći
proteins in urine increased cholesterol in the blood
proteine u mokraći povećan kolesterol u krvi
Proteinuria
glomerulonefritis
Proteinuria
Proteinurij a
Proteinuria
sustava
Proteinuria (1),(3)
proteinurija (1),(3)
Proteinuria (including increased blood creatinine)
Proteinurija (uključujući povišeni kreatinin u krvi)
Proteinuria has been reported in patients treated with lenvatinib, usually occurring early in the course of treatment (see section 4.8, Description of selected adverse reactions).
U bolesnika liječenih lenvatinibom zabilježena je proteinurija koja obično nastaje rano u tijeku liječenja (vidjeti dio 4.8 Opis odabranih nuspojava).
Proteinuria led to permanent treatment discontinuation in 0.8% of patients.
Proteinurija je dovela do trajnog prestanka liječenja u 0,8% bolesnika.
Proteinuria Renal failure
Proteinurija Zatajenje bubrega
Proteinuria*, blood creatinine increased, renal failure*
Proteinurija*, povišenje kreatinina u krvi, zatajenje bubrega
proteinuria,
proteinurija,
proteinuria, blood creatinine increased, dysuria, haematuria
proteinurija, povišen kreatinin u krvi, dizurija, hematurija
proteinuria, dysuria, haematuria
proteinurija, dizurija, hematurija
Proteinuria, haematuria
proteinurija, hematurija
Proteinuria, nephrolithiasis
proteinurija, nefrolitijaza
proteinuria, polyuria, renal impairment
proteinurija, poliurija, oštećenje funkcije bubrega
Proteinuria.
Proteinurija
Proteinuriaa
proteinurijaa
Proteinuriaa,b
proteinurijaa,b,
Proteinuriab,d
proteinurijab,d
proteinuriad
proteinurijad
Proteinurial
17,7
Proteinuria‡
proteinurija
PROTELOS 2 g granules for oral suspension
PROTELOS 2 g granule za oralnu suspenziju
PROTELOS contains aspartame, a source of phenylalanine, which may be harmful for people with phenylketonuria.
PROTELOS sadržava aspartam, izvor fenilalanina, koji može biti štetan za osobe s fenilketonurijom.
PROTELOS is a medicine used to treat severe osteoporosis:
PROTELOS je lijek koji se koristi za liječenje teške osteoporoze:
PROTELOS is available in sachets containing yellow granules for oral suspension.
PROTELOS je dostupan u vrećicama koje sadrže žute granule za pripremu oralne suspenzije.
PROTELOS is contraindicated and must not be used in patients with :
PROTELOS je kontraindiciran i ne smije se koristiti u bolesnika s :
PROTELOS is for oral use.
PROTELOS se uzima kroz usta.
PROTELOS is not intended for use in children and adolescents (below the age of 18).
PROTELOS nije namijenjen za primjenu u djece i mladeži (mlađih od 18 godina).
PROTELOS is only indicated for use in patients with severe osteoporosis at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance.
PROTELOS je indiciran samo za primjenu u bolesnika s teškom osteoporozom s visokim rizikom za nastanak prijeloma, kod kojih liječenje s drugim lijekovima odobrenima za liječenje osteoporoze nije moguće zbog, na primjer, kontraindikacija ili nepodnošenja.
Protelos is unlikely to affect your ability to drive or use machines.
Nije vjerojatno da će PROTELOS utjecati na Vašu sposobnost upravljanja motornim vozilima i strojevima.
Protelos should be taken at least two hours after food, milk, milk products or calcium supplements, preferably at bedtime.
Protelos treba uzeti barem 2 sata nakon hrane, mlijeka, mliječnih proizvoda ili nadopune kalcija, po mogućnosti u vrijeme
PROTELOS should only be used with caution in:
PROTELOS smije se primjenjivati samo uz oprez u:
Protelos strontium ranelate
Protelos stroncijev ranelat
proteolytic activity:
proteolitička aktivnost:
Proteq West Nile
Proteq West Nile.
Proteq West Nile suspension for injection for horses
Proteq West Nile suspenzija za injekciju za konje
ProteqFlu suspension for injection for horses
ProteqFlu suspenzija za injekciju za konje
ProteqFlu-Te suspension for injection for horses
ProteqFlu-Te suspenzija za injekcije za konje
Prothrombin time (PT) is influenced by rivaroxaban in a dose dependent way with a close correlation to plasma concentrations (r value equals 0.98) if Neoplastin is used for the assay.
Rivaroksaban utječe na protrombinsko vrijeme (PV) na način ovisan o dozi, pri čemu postoji bliska korelacija s njegovom koncentracijom u plazmi (r = 0,98) ako se u testu koristi Neoplastin.
Prothrombin time (PT) is influenced by rivaroxaban in a dose dependent way with a close correlation to plasma concentrations (r value equals 0.98) if Neoplastin is used for the assay.
Rivaroksaban utječe na protrombinsko vrijeme (PV) na način ovisan o dozi, pri čemu postoji bliska korelacija s njegovom koncentracijom u plazmi (r vrijednost jednaka 0,98), ako se u testu koristi Neoplastin.
Prothrombin time (PT) Quick or INR
protrombinsko vrijeme (PV) brzo ili INR (internacionalni normirajući omjer)
Prothrombin time (PT) Up to 12 hours
Protrombinsko vrijeme (PT) Do najviše 12 sati
Prothrombin time (≤1 X ULN)b
Protrombinsko vrijeme (≤1 x GGN)b
Protocol 003 evaluated immunogenicity of Gardasil 9 in men 16 through 26 years of age and women 16 through 26 years of age (1,103 Heterosexual Men [HM]; 313 Men Who Have Sex with Men [MSM]; and 1,099 women receiving Gardasil 9).
U Protokolu 003 ocijenjena je imunogenost cjepiva Gardasil 9 u muškaraca u dobi od 16 do 26 godina i žena u dobi od 16 do 26 godina (1103 heteroseksualna muškarca [HM], 313 muškaraca koji imaju spolne odnose s drugim muškarcima [MSM] i 1099 žena primilo je Gardasil 9).
Protocol 006 evaluated the immunogenicity of Gardasil 9 in 921 girls and women (12 through 26 years of age) who had previously been vaccinated with qHPV vaccine.
U Protokolu 006 ocijenjena je imunogenost cjepiva Gardasil 9 u 921 djevojaka i žena (u dobi od 12 do 26 godina) koje su prethodno bile cijepljene cjepivom qHPV.
Protocol 010 evaluated the immunogenicity of 2 doses of Gardasil 9 in girls and boys 9 through 14 years of age and 3 doses of Gardasil 9 in girls 9 through 14 years of age and women 16 through 26 years of age (N=1,518; 753 girls; 451 boys and 314 women).
U Protokolu 010 ocijenjena je imunogenost 2 doze cjepiva Gardasil 9 u djevojčica i dječaka u dobi od 9 do 14 godina i 3 doze cjepiva Gardasil 9 u djevojčica u dobi od 9 do 14 godina te žena u dobi od 16 do 26 godina (N = 1518; 753 djevojčica, 451 dječak i 314 žena).
Protocol defined major bleeding
Veliko krvarenje definirano planom ispitivanja
Protocol defined non-inferiority of once-daily dosing compared with twice-daily dosing was demonstrated if the lower bound of the 95% confidence interval for the difference in proportion of subjects responding (once daily minus twice daily) excluded -12% at Week 48.
Protokolom definirana neinferiornost doziranja jednom dnevno naspram doziranja dva puta dnevno pokazana je ako donja granica 95%-nog intervala pouzdanosti za razliku u proporciji odgovora ispitanika (jednom dnevno minus dva puta dnevno) ne prelazi -12 % u 48. tjednu.
Protocol defined non-inferiority of once-daily dosing compared with twice-daily dosing was demonstrated if the lower bound of the 95% confidence interval for the difference in proportion of subjects responding (once daily minus twice daily) excluded -12% at Week 48.
Protokolom definirana neinferiornost doziranja jednom dnevno naspram doziranja dva puta dnevno pokazana je ako donja granica 95%-tnog intervala pouzdanosti za razliku u proporciji odgovora ispitanika (jednom dnevno minus dva puta dnevno) ne prelazi -12 % u 48. tjednu.